Recent studies comparing the long-acting insulin analogue glargine (GLA) vs. NPH insulin in combination with metformin revealed the advantages of insulin GLA, owing to its flat and long-lasting pharmacodynamic profile in patients with type 2 diabetes [13]. Here, INS is linked to type 2 diabetes mellitus.